Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma.
Skin melanoma, a life-threatening disease, has a recently reported worldwide increase in incidence, despite primary prevention. Skin melanoma statistics emphasize the need for finding markers related to the immune response of the host. The mechanisms that are able to over-power the local immune surveillance comprise molecules that can be valuable markers for diagnosis and prognosis. This article summarizes the immune markers that can monitor the disease stage and evaluate the efficacy of therapeutic interventions. Recent data regarding immunotherapy are presented in the context of tumor escape from immune surveillance and the immune molecules that are both targets and a means of monitoring. Perspectives for developing immune interventions for skin melanoma management and the position of tissue or soluble immune markers as a diagnostic/prognostic panel are evaluated. State-of-the-art technology is emphasized for developing immune molecular signatures for a complex characterization of the patient's immunological status.
Victor Babes' National Institute of Pathology, 99-101 Splaiul Independentei, 050096 Bucharest, Romania. neagu.monica@gmail.com
Monica
M
Neagu
Carolina
C
Constantin
Cristiana
C
Tanase
D014408:Biomarkers, Tumor / Q000032:analysis / Q000097:blood*; D002280:Basal Cell Carcinoma / Q000175:diagnosis* / Q000628:therapy; D003713:Dendritic Cells / Q000378:metabolism; D005819:Genetic Markers; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007694:Killer Cells, Natural / Q000378:metabolism; D008545:Melanoma / Q000097:blood* / Q000276:immunology; D014411:Neoplastic Stem Cells / Q000378:metabolism; D011379:Prognosis; D015398:Signal Transduction; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000628:therapy; D050378:T-Lymphocytes, Regulatory / Q000378:metabolism
D014408:Biomarkers, Tumor; D005819:Genetic Markers